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Abstract
Background: Hypertension and proteinuria are medical complications associated with the multisystemic effects of
long-term hypercortisolism in dogs with hyperadrenocorticism (HAC).
Methods: This study investigated the relationships among adrenocorticotropic hormone (ACTH)-stimulation test
results, systemic blood pressure, and microalbuminuria in clinically-healthy dogs (n = 100), in dogs affected with
naturally occurring pituitary-dependent (PDH; n = 40), or adrenal-dependent hyperadrenocorticism (ADH; n = 30).
Results: Mean systemic blood pressure was similar between clinically healthy dogs and dogs with HAC (p = 0.803).
However the incidence of hypertension was highest in dogs with ADH (p = 0.017), followed by dogs with PDH,
with the lowest levels in clinically healthy dogs (p = 0.019). Presence of microalbuminuria and albuminuria in
clinically healthy dogs and dogs affected with HAC was significantly different (p < 0.001); incidences of albuminuria
followed the same pattern of hypertension; highest incidence in dogs with ADH, and lowest level in clinically
healthy dogs; but microalbuminuria showed a different pattern: clinically healthy dogs had highest incidences and
dogs with ADH had lowest incidence. The presence of albuminuria was not associated with blood pressure values,
regardless of whether dogs were clinically healthy or affected with ADH or PDH (p = 0.306).
Conclusions: Higher incidence of hypertension and albuminuria, not microalbuminuria was seen in dogs affected
with HAC compared to clinically healthy dogs; incidence of hypertension and albuminuria was significantly higher
in dogs affected with ADH compared to PDH. However, presence of albuminuria was not correlated with systemic
blood pressure.
Background
Hyperadrenocorticism (HAC, Cushing’ss y n d r o m e )i sa
common endocrine disorder in dogs and is character-
ized by chronically elevated circulating concentrations of
the steroid hormones produced by the adrenal cortex
(e.g. cortisol) [1]. The multi-systemic effects of long-
term hypercortisolism in dogs results in a variety of
medical complications such as hypertension and protei-
nuria [1-4]. Hypertension develops by several mechan-
isms, including excessive renin concentrations which
lead to activation of the renin-angiotensin system,
increased vascular sensitivity to catecholamine, and
increased concentrations of aldosterone [5-11]. These
conditions warrant both prompt, in-depth evaluation of
organ damage and treatment. For example, glomerular
damage secondary to hypertension may further result in
albuminuria which is associated with deteriorated renal
function [12-17].
Apart from hypertension, many complications asso-
ciated with Cushing’s syndrome in humans are also
linked with increased urinary albumin excretion rate.
These include dyslepidaemia, reduced insulin sensitivity,
and hyper-coagulative status. These complications are
also associated with canine HAC [1,16,18,19].
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amount of albumin (1 to 30 mg/dL) in the urine [16].
Microalbuminuria assays are more sensitive to albumin
loss in the urine than the common urine dipstick, and
urinary protein:creatinine ratio tests can detect protein
loss through the urine with lower limits-of-detection
than urine dipsticks. Microalbuminuria is used as an
indicator in screening for early-stage renal and cardio-
vascular diseases in humans [12,14,17,20,21]. It is a
well-known risk factor associated with deteriorated car-
diovascular mortality and diabetic nephropathy in
human beings [12-14,17]. Similarly, microalbuminuria is
associated with renal and systemic sub-clinical diseases
in dogs and cats [22-24].
The purposes of this study were to report the relation-
ship between ACTH-stimulation tests, systemic blood
pressure, microalbuminuria and albuminuria in dogs
affected with naturally occurring pituitary-dependent
(PDH) and adrenal-dependent hyperadrenocorticism
(ADH).
Methods
Animals
Informed consent was obtained from all dog owners
prior to the study, and number of animals of each breed
in each group are shown in Table 1.
Clinically healthy dogs
One hundred clinically healthy client-owned dogs visit-
ing the National Taiwan University Veterinary Hospital
from 2005 to 2009 for routine health checkups and/or
annual vaccination were included in this study. Of the
clinically healthy dogs, 29 were intact females, 19 were
spayed females, 45 were intact males, and 7 were
castrated males. The average age was 5.1 ± 3.5 years
(range 0.9 to 15 years), and average body weight was
11.6 ± 9.1 kg (range 1.8 to 35.0 kg). Thorough physical
examination, blood pressure measurements and routine
blood work (complete blood counts and biochemical
profiles) were performed to exclude heart and renal dis-
orders that might affect blood pressure or cause micro-
albuminuria or albuminuria.
Dogs affected with hyperadrenocorticism
Medical records of 278 dogs in the National Taiwan
University Veterinary Hospital during 2005-2009 with
clinical signs of HAC and results of ACTH stimulation
tests consistent with hyperadrenocorticism were
screened. Only 70 of these records included conclusive
results from an ACTH stimulation test, ultrasonographic
evidence of adrenal glands, blood pressure measure-
ments and microalbuminuria analysis. Therefore, only
70 dogs were included in the study.
Inclusion criteria of HAC were clinical signs consis-
tent with a diagnosis of HAC (e.g., polydipsia, polyuria,
polyphagia, decreased activity, panting, a potbellied
appearance, and dermatologic problems), results of rou-
tine serum biochemical analyses that were consistent
with a diagnosis of HAC (i.e., elevated activities of hepa-
tic enzymes), and affirmative results of adrenocorticotro-
pic hormone (ACTH) stimulation tests (post-ACTH
cortisol concentration >20 μg/dL) [25]. Dogs with
inconclusive results of ACTH stimulation tests were
excluded from the study. Further differentiation between
PDH or ADH was based upon adrenal ultrasonographic
findings [1,26,27]. Size, shape, presence of nodular
appearance and hyperechoic foci: normal or mild
enlarged adrenal glands were classified as PDH; whereas
adrenal glands with a nodular (or mass) appearance and
hyperechoic foci were classified as ADH [1,26,27].
All included dogs were required to have had an
ACTH stimulation test with intramuscular injection of
0.25 mg synthetic ACTH (Cortrosyn, Organon, The
Netherlands). Informed consent was obtained from all
owners prior to diagnostic testing. Blood samples for
serum cortisol measurements were collected via cephalic
venipuncture immediately before, and 1 hour after syn-
thetic ACTH was injected. Serum cortisol concentra-
tions were measured by a validated radioimmunoassay
Table 1 Breeds and numbers of the 100 clinical healthy
dogs, 40 dogs affected with pituitary-dependent
hyperadrenocorticism (PDH) and 30 dogs affected with
adrenal-dependent hyperadrenocorticism (ADH)
Breed Clinically Healthy PDH ADH
Akita inu 0 0 1
Beagle 1 2 1
Bichon frise 0 1 0
Chihuahua 0 1 0
Cocker Spaniel 2 1 1
Japanese spitz 0 2 1
Golden retriever 2 0 0
Lhasa apso 1 0 0
Maltese terrier 20 7 9
Miniature pinscher 3 1 1
Miniature poodle 10 3 1
Miniature schnauzer 5 2 2
Mixed breed 22 7 2
Papillon 1 0 0
Pekingese 1 0 0
Pomeranian 9 3 3
Pug 1 0 0
Shetland sheep dog 1 0 0
Shihba inu 0 1 0
Shih Tzu 5 4 5
Short-haired dachshund 0 0 1
West Highland white terrier 0 1 0
Yorkshire Terrier 16 4 2
Total 100 40 30
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U.S.A.) [27].
In this study, 70 dogs were affected with HAC, with
the mean age of 11.7 ± 2.7 years and ranged from 4.5 to
18 years. Dogs had a mean body weight of 9.0 ± 7.6 kg
ranging from 2.1 to 43.4 kg. Twenty-seven were spayed
females, 21 were intact males, and 11 each of castrated
males and intact females. Among these 70 cases, 40
dogs affected with PDH and 30 dogs affected with ADH
(functional adrenal tumor). The mean age of the 40
dogs affected with PDH was 10.7 ± 2.7 years, ranging
from 4.5 to 16 years with a mean body weight of 9.9 ±
8.6 kg, ranging from 2.1 to 43.4 kg. Sixteen were spayed
females, 6 were intact females, 12 were intact males and
6 were castrated males. The mean age of the dogs
affected with ADH was 12.9 ± 2.2 years, ranging from 8
to 18 years. This group had a mean body weight of
7.9 ± 5.6 kg, ranging from 3.0 to 24.5 kg. Eleven were
spayed females, 5 were intact females, 9 were intact
males, and 5 were castrated males. Breeds of 70 dogs
affected with HAC are shown in Table 2.
Systemic blood pressure measurement
Systemic blood pressure values of 100 clinically healthy
dogs and 70 dogs affected with (pre-treated) HAC were
evaluated by the same protocol–Doppler sphygmomano-
metry. A Doppler Ultrasonic Flow Detector (Model
811-B, Parks Medical Electronics Inc., U.S.A.) with an
inflatable cuff width of 1.9, 2.5, 3, 4, or 5 cm (depending
on the circumference of the antebrachium) was used.
The cuff was wrapped around the middle part of the
antebrachium, and a Doppler probe coated with ultraso-
nic transmission gel was positioned over the palmar
area to detect blood flow from the arteria digitalis pal-
maris communis. The cuff was then inflated and
deflated to obtain a systemic blood pressure reading via
an aneroid pressure gauge. During systemic blood pres-
sure measurement, the antebrachium was maintained at
the level of the heart. A series of 5 readings (with 10 to
20 seconds between consecutive measurements) was
obtained for each dog, and all measurements were com-
pleted within 6 minutes. To minimize procedural stress,
all dogs were allowed to assume a comfortable position
with only gentle restraint by their owners. The dogs
remained in the same position throughout systemic
blood pressure measurement. The final systemic blood
pressure value was calculated as the mean of 5 readings
[28]. The heart rate was manually recorded by pulse
Doppler ultrasound detection over a period of 20 sec-
onds after the systemic blood pressure value was mea-
sured. For this study, hypotension, normotension and
hypertension were defined as <100 mmHg, 100-160
mmHg, and >160 mmHg, respectively.
Microalbuminuria assay and urinary albumin:creatinine
ratio
Freshly voided urine samples from 100 clinically healthy
dogs and 70 dogs affected with (pre-treated) HAC were
collected. Urine albumin analysis was carried out within
four hours after the freshly voided urine samples were
collected. Urine samples with hematuria (≥10 RBC/high
power of field), pyuria (≥5 WBC/hpf), or bacteriuria was
excluded after a light-microscopic examination of urine
sediment. The urine albumin and creatinine concentra-
tions were semi-quantitated (Clinitek Microalbumin
Reagent Strips and Clinitek Status Analyser, Bayer Diag-
nostic Mfg. Ltd., UK) and urinary albumin:creatinine
ratio (UACR) was calculated accordingly. In this study,
no microalbuminuria, microalbuminuria and albuminuria
were defined as UACR < 30 mg/g (0.03), 30-300 mg/g
(0.03-0.3), and >300 mg/g (0.3), respectively.
Statistical analysis
Comparison of systemic blood pressure between clini-
cally healthy dogs and dogs affected with either PDH or
ADH were evaluated by means of ANOVA. Relationship
between post-ACTH cortisol concentrations and sys-
temic blood pressure was analyzed by use of linear
Table 2 Systemic blood pressure (SBP) and status of urine albumin excretion in clinically healthy dogs and dogs
affected with pituitary-dependent hyperadrenocorticism (PDH) or adrenal-dependent hyperadrenocorticism (ADH)
Clinically healthy dogs (n = 100) PDH (n = 40) ADH (n = 30)
Mean SBP (mmHg) 152.8 ± 27.3 142.2 ± 24.9 164.1 ± 36.7†
Hypotension % (n) 1% (1/100) 0 0
Normotension % (n) 87% (87/100) 80% (32/40) 53.3% (16/30)
Hypertension % (n) 12% (12/100) 20% (8/40) 46.7% (14/30)*†
Status of urine albumin
No microalbuminuria % (n) 53% (53/100) 15% (6/40) 10% (3/30)
Microalbuminuria % (n) 45% (45/100) 52.5% (21/40) * 20% (6/30) *†
Albuminuria % (n) 2% (2/100) 32.5% (13/40) * 70% (21/30) *†
* p < 0.05 relative to clinically healthy dogs. † p < 0.05 relative to PDH.
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microalbuminuria status (no microalbuminuria, microal-
buminuria and albuminuria) and health status (clinically
healthy versus HAC) were evaluated by Pearson’sc h i -
square test. All statistical analyses were performed using
commercially available software (SPSS, version 13.0,
SSPS Inc, U.S.A.). Continuous data are presented as
mean ± SD. Statistical significance was determined by a
p value < 0.05.
Results
Systemic blood pressure and presence of
microalbuminuria/albuminuria in clinically normal dogs (n
= 100)
The mean systemic pressure of 100 clinically healthy
dogs was 152.8 ± 27.3 mmHg. One (1%, 1/100) was
hypotensive, 87% (87/100) were normotensive, and 12%
(12/100) were hypertensive. Among the 100 clinically
healthy dogs, 53% (53/100) did not have microalbumi-
nuria, 45% (45/100) had microalbuminuria, and 2%
(2/100) had albuminuria (Table 2).
Systemic blood pressure and microalbuminuria/
albuminuria in dogs affected with HAC (n = 70)
The mean systemic arterial pressure in dogs affected
with HAC was 151.7 ± 32.1 mmHg. None was hypoten-
sive, 68.6% (48/70) were normotensive, and 31.4%
(22/70) were hypertensive. In 70 dogs with HAC, 12.9%
(9/70) did not have microalbuminuria, 38.6% (27/70)
had microalbuminuria, and 48.6% (34/70) had albumi-
nuria (Table 2).
Systemic blood pressure, presence of microalbuminuria/
albuminuria and results of ACTH stimulation tests in dogs
affected with PDH (n = 40)
The mean systemic blood pressure in dogs affected with
PDH was 142.2 ± 24.9 mmHg. None was categorized as
hypotensive, 80% (32/40) were normotensive, and 20%
(8/40) were hypertensive. Among the 40 dogs affected
with PDH, 15% (6/40) did not have albuminuria, 52.5%
(21/40) had microalbuminuria, and 32.5% (13/40) had
albuminuria. Pre- and post-ACTH cortisol concentra-
tions in the dogs affected with PDH were 4.6 ± 2.9 (ran-
ging from 1.9 to 14.1) and 25.5 ± 11.6 (ranging from
21.6-63.1) μg/dL, respectively (Table 2).
Systemic blood pressure, presence of microalbuminuria/
albuminuria and results of ACTH stimulation tests in dogs
affected with ADH (n = 30)
The mean systemic blood pressure in dogs affected with
ADH was 164.1 ± 36.7 mmHg. None was hypotensive,
53.3% (16/30) were normotensive, and 46.7% (14/30)
were hypertensive. Among the 30 dogs with ADH, 10%
(3/30) did not have microalbuminuria, 20% (6/30) had
microalbuminuria, and 70% had albuminuria. Pre- and
post-ACTH cortisol concen t r a t i o n si nd o g sa f f e c t e d
with ADH were 8.5 ± 6.0 (ranging from 2.9 to 28.7) and
33.2 ± 23.7 (ranging from 23.6-110.2) μg/dL, respectively
(Table 2).
Comparison of systemic blood pressure and presence of
microalbuminuria/albuminuria between clinically healthy
dogs and dogs affected with HAC
The mean systemic blood pressure was not different
between clinically healthy dogs and dogs with HAC (p =
0.803). However, incidence of hypertension between
clinically healthy dogs and dogs affected with HAC was
significantly different (p = 0.019). Presence of microal-
buminuria and albuminuria in clinically healthy dogs
and dogs affected with HAC was significantly different
(p < 0.001); significantly higher incidence of microalbu-
minuria, but significantly lower incidence of albuminuria
in clinically healthy dogs compared to dogs affected with
HAC. Overall, presence of microalbuminuria or albumi-
nuria was not associated with the status of blood pres-
sure in either clinically healthy dogs or dogs with HAC
(p = 0.141).
Comparison of systemic blood pressure, presences of
microalbuminuria/albuminuria and results of ACTH
stimulation test between dogs affected with PDH and
ADH
The mean systemic blood pressure was significantly
different between dogs affected with PDH and ADH
(p = 0.004). Incidence of hypertension in dogs affected
with PDH and ADH was significantly different
(p = 0.017). Presence of microalbuminuria and albumi-
nuria in dogs affected with PDH and ADH was signifi-
cantly different (p = 0.007). However, albuminuria was not
associated with the status of blood pressure (p = 0.306).
Both pre- and post-ACTH cortisol concentrations
between dogs affected with PDH and ADH were signifi-
cantly different (p < 0.001). No correlation between sys-
temic blood pressure in either pre-ACTH (r = 0.095,
p = 0.479) or post-ACTH cortisol concentrations
(r = 0.130, p = 0.326) was found.
Overall, the incidence of hypertension was highest in
dogs with ADH, followed by dogs with PDH, with the
lowest levels in clinically healthy dogs (p = 0.019); inci-
dences of albuminuria followed the same pattern: highest
incidence in dogs with ADH, and lowest level in clinically
healthy dogs (p < 0.001); but microalbuminuria showed a
different pattern: clinically healthy dogs had highest inci-
dence and dogs with ADH had lowest incidence.
Discussion
The incidence of hypertension in dogs affected with
HAC has been reported to range from 52.6 (n = 10/16)
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of hypertension in dogs with HAC was 46.7%, which
was significantly higher than the 12% incidence observed
in clinically healthy dogs, supporting previous observa-
tions that dogs affected by HAC tend to have hyperten-
sion [3,4]. However, the incidence of hypertension in
dogs affected with HAC was lower than that reported in
previous studies. Different methods of blood pressure
measurements, definition of hypertension, and case
numbers may explain lower incidence in this study. The
degree of hypertension is also positively correlated with
the duration of the condition rather than with cortisol
concentrations [11,18]. In this study, the condition of
hyperadrenocorticism was newly diagnosed. Systemic
blood pressure was measured at the initial diagnosis.
A higher incidence of hypertension might be seen at
later stages of the condition.
In this study, higher systemic blood pressure and higher
incidence of hypertension was associated with ADH com-
pared to PDH. This finding has not been reported in dogs
affected with hyperadrenocorticism. However, no correla-
tion between the cortisol concentrations and systemic
blood pressure was found. Similar results were also
reported in human patients with Cushing’ss y n d r o m e
[11,18]. The concentration of cortisol alone may not cause
hypertension. Many factors have been found to be
involved in development of hypertension in human
patients with Cushing’s syndrome, including the duration
of hypercortisolaemia, impaired microvascular reactivity,
endothelial dysfunctions, and hyperaldosteronemia- asso-
ciated arterial wall stiffness and fibrosis [11,18,19,29].
Higher plasma aldosterone concentrations were reported
in dogs affected with ADH than in dogs with PDH [6,30].
Nevertheless, aldosterone was not involved in the develop-
ment of hypertension in dogs with PDH [30]. Further
study regarding association between vascular stiffness,
myocardial reactivity and systemic blood pressure in dogs
affected with either PDH or ADH is warranted.
Incidence of microalbuminuria in clinically healthy
dogs in this study (45%) was similar to previous studies,
ranging from 19 to 52% [31,32]. Surprisingly, a signifi-
cantly lower incidence of microalbuminuria, but a
higher incidence of albuminuria was observed in dogs
affected with HAC compared to clinically healthy dogs.
Microalbuminuria is a well-known risk factor associated
with deteriorated renal and cardiovascular diseases in
humans [12,14,17,20,21]. It is also associated with survi-
val time in chronic renal failure [22]. Nonetheless,
microalbuminuria was also found to be associated with
various underlying systemic diseases, such as neoplasia,
infectious diseases, and immune or inflammatory dis-
eases [24,32]. Due to the high incidence of microalbumi-
nuria in clinically healthy dogs and the association of
this condition with various systemic disorders, the
microalbuminuria test may be more useful to screen for
subclinical disorders than to detect specific diseases.
In this study, incidence of hypertension and albumi-
nuria was significantly higher in dogs affected with
ADH compared to PDH. This finding has not been
reported in dogs affected with HAC. The correlation
between systemic blood pressure and albuminuria would
be anticipated in dogs with HAC, however, this was not
supported in this study. Hypertension is not the only
factor associated with presence of albuminuria.
Increased urinary albumin excretion rate is also linked
to dyslepidaemia, reduced insulin sensitivity, impaired
endothelial function and hyper-coagulative status [7].
These complications are commonly seen in both human
and canine patients with Cushing’ss y n d r o m e
[1,16,18,19]. Glomerular changes and subsequently,
increases in urinary protein excretion were found with
chronic glucocorticoid use [33,34]. These may explain
the disassociation between albuminuria and blood pres-
sure in these dogs.
The cause of albuminuria in dogs affected with HAC
can not be answered in this study. Nevertheless, long-
term monitoring of albuminuria in terms of treatment
and survival time is needed to clarify the importance of
albuminuria and HAC in dogs.
Conclusions
Incidences of hypertension and albuminuria, but not
microalbuminuria, were highest in dogs affected with
ADH, followed by dogs with PDH, with the lowest levels
observed in clinically healthy dogs. However, the pre-
sence of albuminuria was not correlated with systemic
blood pressure.
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